
    
      A randomized, double-blind, placebo-controlled, Phase 3 study of 24 weeks duration.
      Approximately 600 males and females aged ≥18 years with clinical or genetic heterozygous FH
      who fulfill the inclusion and exclusion criteria will be enrolled. Patients will be
      randomized in a 2:1 ratio to LIB003 (400 patients) or placebo (200 patients) administered SC
      Q4W (≤31 days). The study will consist of a Screening Period and a Treatment Period. The
      total study duration will be up to 35 weeks which includes up to an 11-week Screening Period
      (which may include up to a 8-week washout) and 24 weeks of study drug treatment.
    
  